R C Dockens

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi request reprint Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans
    R C Dockens
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA
    Drug Metab Dispos 28:973-80. 2000
  2. ncbi request reprint Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range
    Randy C Dockens
    Bristol Myers Squibb Comapny, Princeton, NJ 08543, USA
    J Clin Pharmacol 46:1308-12. 2006
  3. ncbi request reprint Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans
    Randy C Dockens
    Clinical Discovery, Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Biopharm Drug Dispos 28:393-402. 2007
  4. doi request reprint Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder
    Vladimir Coric
    Bristol Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA
    Depress Anxiety 27:417-25. 2010
  5. ncbi request reprint 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats
    Harvey Wong
    Department of Metabolism and Pharmacokinetics, Pharmaceutical Research Institute, Bristol Myers Squibb, Wallingford, Connecticut 06492 7660, USA
    Drug Metab Dispos 35:1387-92. 2007
  6. ncbi request reprint Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa
    Edyta J Frackiewicz
    Briston Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
    Ann Pharmacother 36:225-30. 2002
  7. ncbi request reprint Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction
    John B Kostis
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
    Clin Pharmacokinet 41:445-52. 2002

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans
    R C Dockens
    Department of Metabolism and Pharmacokinetics, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, USA
    Drug Metab Dispos 28:973-80. 2000
    ..Approximately 40 to 50% of the radioactivity in rat and dog plasma was accounted for by parent drug whereas, in humans, approximately 60% of the plasma radioactivity was accounted for by ifetroban acylglucuronide...
  2. ncbi request reprint Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range
    Randy C Dockens
    Bristol Myers Squibb Comapny, Princeton, NJ 08543, USA
    J Clin Pharmacol 46:1308-12. 2006
    ..6OHB was rapidly formed following buspirone administration, and exposure increased proportionally with buspirone dose. Further research regarding the safety and efficacy of 6OHB itself is warranted...
  3. ncbi request reprint Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans
    Randy C Dockens
    Clinical Discovery, Bristol Myers Squibb Company, Princeton, NJ 08543, USA
    Biopharm Drug Dispos 28:393-402. 2007
    ..All compounds were well tolerated. There seemed to be no advantage of one of the enantiomers of 6OHB over the racemate. Therefore, the racemate was chosen for further clinical development...
  4. doi request reprint Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder
    Vladimir Coric
    Bristol Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA
    Depress Anxiety 27:417-25. 2010
    ..This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD)...
  5. ncbi request reprint 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats
    Harvey Wong
    Department of Metabolism and Pharmacokinetics, Pharmaceutical Research Institute, Bristol Myers Squibb, Wallingford, Connecticut 06492 7660, USA
    Drug Metab Dispos 35:1387-92. 2007
    ..As a whole, these preclinical data suggest that 6-OH-buspirone probably contributes to the clinical efficacy of buspirone as an anxiolytic agent...
  6. ncbi request reprint Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa
    Edyta J Frackiewicz
    Briston Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
    Ann Pharmacother 36:225-30. 2002
    ..To investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of the dopamine transporter antagonist brasofensine (BMS-204756) in patients with Parkinson's disease receiving levodopa/carbidopa treatment...
  7. ncbi request reprint Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction
    John B Kostis
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
    Clin Pharmacokinet 41:445-52. 2002
    ..The aim of this study was to examine the pharmacokinetics and functional activity of a single intravenous bolus dose of lanoteplase with those of a bolus plus two-step infusion of alteplase...